AbbVie’s pending Allergan takeover moves closer after drug divestments
28-01-2020
AbbVie to acquire Allergan for $63bn
25-06-2019
rafapress / Shutterstock.com
Allergan has struck a deal with two generic manufacturers to resolve a long-running patent infringement suit over its antidepressant drug Fetzima (Levomilnacipran).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Allergan, Fetzima, US District Court for the District of New Jersey, MSN Laboratories, Aurobindo Pharma, generics
